November 2023 Publications
- Data-driven epidemiologic approach to conducting site feasibility for a global phase III tuberculosis vaccine clinical trial. Mui WL, Parekh FK, Tseng AS, Toro J, Craig T, Ndugga M, Schmidt AC, Dagnew AF, Penz C, Belai G. PLOS Glob Public Health. 2023 Nov. doi: 10.1371/journal.pgph.0002544.
- Intravenous Bacille Calmette-Guérin vaccination protects simian immunodeficiency virus-infected macaques from tuberculosis. Larson EC, Ellis-Connell AL, Rodgers MA, Gubernat AK, Gleim JL, Moriarty RV, Balgeman AJ, Ameel CL, Jauro S, Tomko JA, Kracinovsky KB, Maiello P, Borish HJ, White AG, Klein E, Bucsan AN, Darrah PA, Seder RA, Roederer M, Lin PL, Flynn JL, O’Connor SL, Scanga CA. Nat Microbiol. 2023 Nov. doi: 10.1038/s41564-023-01503-x. Epub 2023 Oct 9.
- The TB Vaccine Accelerator Council: harnessing the power of vaccines to end the tuberculosis epidemic. Ghebreyesus TA, Lima NT. Lancet Infect Dis. 2023 Nov. doi: 10.1016/S1473-3099(23)00589-3.
- Construction and evaluation of a novel multi-antigenic Mycobacterium tuberculosis subunit vaccine candidate BfrB-GrpE/DPC. Niu H, Cao Q, Zhang T, Du Y, He P, Jiao L, Wang B, Zhu B, Hu L, Zhang Y. Int Immunopharmacol. 2023 Nov. doi: 10.1016/j.intimp.2023.111060. Epub 2023 Oct 18.
- A novel multistage antigens ERA005f confer protection against Mycobacterium tuberculosis by driving Th-1 and Th-17 type T cell immune responses. Fan X, Zhao X, Wang R, Li M, Luan X, Wang R, Wan K, Liu H. Front Immunol. 2023 Nov. doi: 10.3389/fimmu.2023.1276887.
- Mycobacterium tuberculosis-specific memory T cells in bronchoalveolar lavage of patients with pulmonary tuberculosis. Li J, Jing Q, Hu Z, Wang X, Hu Y, Zhang J, Li L. Cytokine. 2023 Nov. doi: 10.1016/j.cyto.2023.156374. Epub 2023 Sep 30.
- An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials. Hill PC, Cobelens F, Martinez L, Behr MA, Churchyard G, Evans T, Fiore-Gartland AJ, Garcia-Basteiro AL, Hanekom W, Rangaka MX, Vekemans J, White RG. J Infect Dis. 2023 Nov 2. doi: 10.1093/infdis/jiad356.
- Improving Tuberculosis Vaccine Trial Efficiency: A Tough Nut to Crack. McShane H. J Infect Dis. 2023 Nov 2. doi: 10.1093/infdis/jiad360.
- Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Zhou F, Zhang D. Front Immunol. 2023 Nov 2. doi: 10.3389/fimmu.2023.1238649.
- Structural and Functional Insights into the Stealth Protein CpsY of Mycobacterium tuberculosis. Liu D, Yuan C, Guo C, Huang M, Lin D. Biomolecules. 2023 Nov 3. doi: 10.3390/biom13111611.
- Inability of the BCG vaccine to protect mice of the H2f haplotype at advanced stages of TB infection is associated with defective CD4+ T-cell activation in spleen. Korotetskaya M, Baikuzina P, Apt A. Tuberculosis (Edinb). 2023 Nov 10. doi: 10.1016/j.tube.2023.102429. Online ahead of print
- Association of lineage 4.2.2 of Mycobacterium tuberculosis with the 63-bp deletion variant of the mpt64 gene. Song Z, He W, Pei S, Zhao B, Cao X, Wang Y, He P, Liu D, Ma A, Ou X, Xia H, Wang S, Liu C, Zhao Y. Microbiol Spectr. 2023 Nov 10. doi: 10.1128/spectrum.01842-23. Epub ahead of print.
- Mycobacterium tuberculosis Fatty Acyl-CoA Synthetase fadD33 Promotes Bacillus Calmette-Guérin Survival in Hostile Extracellular and Intracellular Microenvironments in the Host. Zhu Y, Shi H, Tang T, Li Q, Peng Y, Bermudez LE, Hu C, Chen H, Guo A, Chen Y. Cells. 2023 Nov 11. doi: 10.3390/cells12222610.
- Current Perspectives and Challenges of MAIT Cell-Directed Therapy for Tuberculosis Infection. Chengalroyen MD. Pathogens. 2023 Nov 12. doi: 10.3390/pathogens12111343.
- Vaccine development against tuberculosis before and after Covid-19. Kaufmann SHE. Front Immunol. 2023 Nov 15. doi: 10.3389/fimmu.2023.1273938.
- T Cell Response in Tuberculosis-Infected Patients Vaccinated against COVID-19. Cavalcante-Silva LHA, Leite EG, Almeida FS, Andrade AG, Comberlang FC, Lucena CKR, Pachá ASC, Csordas BG, Keesen TSL. Microorganisms. 2023 Nov 19. doi: 10.3390/microorganisms11112810.
- Disseminated tuberculosis complicating Bacillus Calmette-Guérin (BCG) vaccine as only presentation of severe combined immunodeficiency (SCID): A report of 3 cases. Omer K, Algaly G, Mohamed Salih OA. Qatar Med J. 2023 Nov 19. doi: 10.5339/qmj.2023.sqac.9.
- Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development. Looney MM, Hatherill M, Musvosvi M, Flynn J, Kagina BM, Frick M, Kafuko Z, Schmidt A, Southern J, Wilder-Smith A, Tippoo P, Paradkar V, Popadić D, Scriba TJ, Hanekom W, Giersing B. Vaccine. 2023 Nov 22. doi: 10.1016/j.vaccine.2023.10.026. Epub 2023 Oct 21.
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Lancet Infect Dis. 2023 Nov 24. doi: 10.1016/S1473-3099(23)00501-7. Epub ahead of print.
- Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control. Gong W, Du J. Lancet Infect Dis. 2023 Nov 24. Doi: 10.1016/S1473-3099(23)00514-5. Epub ahead of print.
- Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine model. Plumlee CR, Barrett HW, Shao DE, Lien KA, Cross LM, Cohen SB, Edlefsen PT, Urdahl KB. PLoS Pathog. 2023 Nov 27. doi: 10.1371/journal.ppat.1011825.
- Activation dynamics of antigen presenting cells in vivo against Mycobacterium bovis BCG in different immunized route. Xu Z, Li X, Xia A, Zhang Z, Wan J, Gao Y, Meng C, Chen X, Jiao XA. BMC Immunol. 2023 Nov 27. doi: 10.1186/s12865-023-00589-6.
- Proteome and immunogenicity differences in BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c during planktonic growth in 7H9 and Proskauer Beck media. Flores-Valdez MA, Velázquez-Fernández JB, Pedroza-Roldán C, Aceves-Sánchez MJ, Gutiérrez-Ortega A, López-Romero W, Barba-León J, Rodríguez-Campos J. Tuberculosis (Edinb). 2023 Nov 28. doi: 10.1016/j.tube.2023.102432. Epub ahead of print.
- A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation. Jiang F, Han Y, Liu Y, Xue Y, Cheng P, Xiao L, Gong W. Front Immunol. 2023 Nov 29. doi: 10.3389/fimmu.2023.1280299.
- Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo. Blazevic A, Edwards RL, Xia M, Eickhoff CS, Hamzabegovic F, Meza KA, Ning H, Tennant J, Mosby KJ, Ritchie JC, Girmay T, Lai L, McCullough M, Beck A, Kelley C, Edupuganti S, Kabbani S, Buchanan W, Makhene MK, Voronca D, Cherikh S, Goll JB, Rouphael NG, Mulligan MJ, Hoft DF. J Infect Dis. 2023 Nov 29. doi: 10.1093/infdis/jiad441. Epub ahead of print.
- Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report. Gsell PS, Giersing B, Gottlieb S, Wilder-Smith A, Wu L, Friede M. Vaccine. 2023 Nov 30. doi: 10.1016/j.vaccine.2023.10.027. Epub 2023 Nov 8.
- Mucosal recombinant BCG vaccine induces lung-resident memory macrophages and enhances trained immunity via mTORC2/HK1-mediated metabolic rewiring. Peng X, Zhou Y, Zhang B, Liang X, Feng J, Huang Y, Weng S, Xu Y, Su H. J Biol Chem. 2023 Nov 30. doi: 10.1016/j.jbc.2023.105518. Epub ahead of print.